Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,080.36 +5.68 (+0.53%)
Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
MarketBeat Week in Review – 12/29 - 01/02 ↗
Via MarketBeat
News headline image
The Great 2026 Rebalancing: Institutional Giants Pivot from AI Hype to Industrial Execution
As the opening bell rang for the first trading session of 2026, the financial world witnessed the commencement of what analysts are calling "The Great Rebalancing." Institutional fund managers,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
S&P 500 Tests Critical Support Levels as 2026 Kicks Off Under Technical Pressure
The S&P 500 (INDEXSP:.INX) entered the new year on a tenuous footing, grappling with a rare four-session losing streak that capped off an otherwise stellar 2025. After finishing the final trading day... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Alphabet’s Golden Year: Inside the 2025 Rally and the Future of the AI Giant
As we enter 2026, the narrative surrounding the world’s most dominant information gateway has shifted from one of existential threat to unprecedented strength. Alphabet Inc. (NASDAQ: GOOGL / GOOG) has... 
Via PredictStreet
Topics Artificial Intelligence Initial Public Offering
News headline image
2 S&P 500 Stocks with Impressive Fundamentals and 1 We Avoid
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
Navigating the Neutral Rate: Wall Street's 2026 Outlook Forecasts Growth Amidst AI Maturity
As the opening bell prepares to ring for the first time in 2026, the American investor finds themselves at a unique crossroads of technological maturation and economic normalization. Following a robust... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade
News headline image
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗
These two companies have very different risk-reward profiles. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Where Will Pfizer Be in 5 Years? ↗
Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗
Via MarketBeat
News headline image
So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO. ↗
Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion. 
Via Investor's Business Daily
News headline image
Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine
The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI... 
Via TokenRing AI
Topics Artificial Intelligence Bonds
News headline image
The 2026 Earnings Gauntlet: Can Corporate Profits Justify Wall Street's High-Wire Act?
As the clock strikes midnight on December 31, 2025, the U.S. stock market stands at a historic crossroads. The S&P 500 has closed the year at record highs, fueled by a relentless surge in artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Could This Potential Move Boost Eli Lilly's Prospects? ↗
The stock already looks unstoppable, and this move won't hurt its momentum. 
Via The Motley Fool
News headline image
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake ↗
Via MarketBeat
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier
As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
S&P 500 Hovers at the Flatline: A Masterclass in Market Resilience or the Quiet Before a 2026 Storm?
As the sun sets on 2025, the S&P 500 is holding its breath. In a trading session characterized by thin holiday volume and a notable absence of institutional conviction, the benchmark index spent much... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk Stock Dropped on Monday ↗
The cost of Wegovy is about to decrease significantly in a populous overseas market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.